Prelude Therapeutics posts new investor presentation

Prelude Therapeutics Incorporated furnished an update for investors by making new presentation materials available.

Rhea-AI Filing Summary

Prelude Therapeutics Incorporated furnished an update for investors by making new presentation materials available. The company plans to use this investor presentation in meetings beginning on January 9, 2026, and has attached the materials as Exhibit 99.1. The information in the presentation and the related report is being furnished rather than filed, which means it is not subject to certain liability provisions and is not automatically incorporated into other securities offering documents.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Prelude Therapeutics (PRLD) disclose in this 8-K?

Prelude Therapeutics furnished new investor presentation materials that it plans to use in presentations starting January 9, 2026, attached as Exhibit 99.1.

What is included as Exhibit 99.1 for Prelude Therapeutics (PRLD)?

Exhibit 99.1 contains a presentation with information about Prelude Therapeutics that management will use in investor meetings.

Is the Prelude Therapeutics (PRLD) investor presentation considered filed with the SEC?

No. The investor presentation and related information are being furnished, not filed, and are not incorporated by reference into other Securities Act or Exchange Act filings.

When will Prelude Therapeutics (PRLD) begin using the new investor presentation?

Prelude Therapeutics intends to use the new investor presentation in investor meetings commencing January 9, 2026.

Which executive signed this Prelude Therapeutics (PRLD) report?

The report was signed by Bryant Lim, who serves as Chief Financial Officer and Chief Legal Officer of Prelude Therapeutics.

What other exhibit is referenced in this Prelude Therapeutics (PRLD) report?

The report also references Exhibit 104, a Cover Page Interactive Data File embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 07:30 AM EST Learn about SEC filing dates

false000167866000016786602026-01-092026-01-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

Prelude Therapeutics Incorporated

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-39527				81-1384762
(State or other jurisdiction of incorporation or organization)		(Commission File Number)				(I.R.S. Employer Identification No.)
175 Innovation Boulevard Wilmington, Delaware				19805
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (302) 467-1280

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		PRLD		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

The Company has prepared investor presentation materials with information about the Company, which it intends to use as part of investor presentations commencing January 9, 2026. A copy of the investor presentation materials to be used by management for presentations is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished, but shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PRELUDE THERAPEUTICS INCORPORATED
Date: January 9, 2026	By:	/s/ Bryant Lim
		Bryant Lim
		Chief Financial Officer and Chief Legal Officer